U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Digestive System Carcinoma

MedGen UID:
1663290
•Concept ID:
C4726547
•
Neoplastic Process
Synonym: Refractory Gastrointestinal System Carcinoma

Definition

A carcinoma hat arises from any part of the digestive system and is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Digestive System Carcinoma

Professional guidelines

PubMed

Intrahepatic cholangiocarcinoma: Evolving strategies in management and treatment.
Bragazzi MC, Venere R, Ribichini E, Covotta F, Cardinale V, Alvaro D
Dig Liver Dis 2024 Mar;56(3):383-393. Epub 2023 Sep 16 doi: 10.1016/j.dld.2023.08.052. PMID: 37722960
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma.
Dondossola D, Ghidini M, Grossi F, Rossi G, Foschi D
World J Gastroenterol 2020 Jul 7;26(25):3542-3561. doi: 10.3748/wjg.v26.i25.3542. PMID: 32742125Free PMC Article

Recent clinical studies

Etiology

Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R
Cancer Immunol Immunother 2023 Nov;72(11):3765-3772. Epub 2023 Aug 28 doi: 10.1007/s00262-023-03528-x. PMID: 37638979Free PMC Article
FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements.
Gandhy SU, Casak SJ, Mushti SL, Cheng J, Subramaniam S, Zhao H, Zhao M, Bi Y, Liu G, Fan J, Adeniyi O, Charlab R, Kufrin D, Thompson MD, Jarrell K, Auth D, Lemery SJ, Pazdur R, Kluetz PG, Fashoyin-Aje LA
Clin Cancer Res 2023 Oct 13;29(20):4027-4031. doi: 10.1158/1078-0432.CCR-23-1042. PMID: 37289037Free PMC Article
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H
J Clin Oncol 2016 May 1;34(13):1448-54. Epub 2016 Feb 16 doi: 10.1200/JCO.2015.63.5995. PMID: 26884585

Diagnosis

NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J
Br J Cancer 2024 Feb;130(3):476-482. Epub 2023 Dec 22 doi: 10.1038/s41416-023-02534-1. PMID: 38135713Free PMC Article
Refractory Diarrhea and Gastric Adenocarcinoma, Just a Coincidence?
Lu SY, Zhang H, Chen Y
Gastroenterology 2024 Mar;166(3):e1-e5. Epub 2023 Oct 6 doi: 10.1053/j.gastro.2023.09.044. PMID: 37806458
Community Awareness and Education: In the West and Southeast Asia.
Morement H, Khuntikeo N
Recent Results Cancer Res 2023;219:349-359. doi: 10.1007/978-3-031-35166-2_12. PMID: 37660339
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
Al-Hader A, Al-Rohil RN, Han H, Von Hoff D
World J Gastroenterol 2017 Dec 7;23(45):7945-7951. doi: 10.3748/wjg.v23.i45.7945. PMID: 29259370Free PMC Article
Palliative urinary diversion.
Perinetti EP
Surg Clin North Am 1982 Dec;62(6):1025-34. doi: 10.1016/s0039-6109(16)42882-3. PMID: 6184786

Therapy

The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas.
Deng J, Pan T, Wang D, Hong Y, Liu Z, Zhou X, An Z, Li L, Alfano G, Li G, Dolcetti L, Evans R, Vicencio JM, Vlckova P, Chen Y, Monypenny J, Gomes CAC, Weitsman G, Ng K, McCarthy C, Yang X, Hu Z, Porter JC, Tape CJ, Yin M, Wei F, Rodriguez-Justo M, Zhang J, Tejpar S, Beatson R, Ng T
EMBO Mol Med 2024 Sep;16(9):2080-2108. Epub 2024 Aug 5 doi: 10.1038/s44321-024-00105-2. PMID: 39103698Free PMC Article
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R
Cancer Immunol Immunother 2023 Nov;72(11):3765-3772. Epub 2023 Aug 28 doi: 10.1007/s00262-023-03528-x. PMID: 37638979Free PMC Article
A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study.
Türeci O, Sahin U, Schulze-Bergkamen H, Zvirbule Z, Lordick F, Koeberle D, Thuss-Patience P, Ettrich T, Arnold D, Bassermann F, Al-Batran SE, Wiechen K, Dhaene K, Maurus D, Gold M, Huber C, Krivoshik A, Arozullah A, Park JW, Schuler M
Ann Oncol 2019 Sep 1;30(9):1487-1495. doi: 10.1093/annonc/mdz199. PMID: 31240302Free PMC Article
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
Al-Hader A, Al-Rohil RN, Han H, Von Hoff D
World J Gastroenterol 2017 Dec 7;23(45):7945-7951. doi: 10.3748/wjg.v23.i45.7945. PMID: 29259370Free PMC Article
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, Liu W, Tong J, Liu Y, Xu R, Wang Z, Wang Q, Ouyang X, Yang Y, Ba Y, Liang J, Lin X, Luo D, Zheng R, Wang X, Sun G, Wang L, Zheng L, Guo H, Wu J, Xu N, Yang J, Zhang H, Cheng Y, Wang N, Chen L, Fan Z, Sun P, Yu H
J Clin Oncol 2016 May 1;34(13):1448-54. Epub 2016 Feb 16 doi: 10.1200/JCO.2015.63.5995. PMID: 26884585

Prognosis

The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas.
Deng J, Pan T, Wang D, Hong Y, Liu Z, Zhou X, An Z, Li L, Alfano G, Li G, Dolcetti L, Evans R, Vicencio JM, Vlckova P, Chen Y, Monypenny J, Gomes CAC, Weitsman G, Ng K, McCarthy C, Yang X, Hu Z, Porter JC, Tape CJ, Yin M, Wei F, Rodriguez-Justo M, Zhang J, Tejpar S, Beatson R, Ng T
EMBO Mol Med 2024 Sep;16(9):2080-2108. Epub 2024 Aug 5 doi: 10.1038/s44321-024-00105-2. PMID: 39103698Free PMC Article
Commentary on "Predicting Survival Using Whole-Liver MRI Radiomics in Patients with Hepatocellular Carcinoma After TACE Refractoriness".
Najafi A
Cardiovasc Intervent Radiol 2024 Jul;47(7):978-979. Epub 2024 Jun 24 doi: 10.1007/s00270-024-03794-x. PMID: 38914767
Carcinoid syndrome caused by a pulmonary carcinoid mimics intestinal manifestations of ulcerative colitis: A case report.
Reyes CM, Klein H, Stögbauer F, Einwächter H, Boxberg M, Schirren M, Safi S, Hoffmann H
World J Gastroenterol 2023 Sep 7;29(33):5014-5019. doi: 10.3748/wjg.v29.i33.5014. PMID: 37731996Free PMC Article
Molecularly guided treatment of metastatic parotid gland carcinoma in adults.
Taghizadeh H, Müllauer L, Mader RM, Füreder T, Prager GW
Wien Klin Wochenschr 2021 Jan;133(1-2):32-40. Epub 2020 Dec 9 doi: 10.1007/s00508-020-01778-8. PMID: 33296026Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Clinical prediction guides

The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas.
Deng J, Pan T, Wang D, Hong Y, Liu Z, Zhou X, An Z, Li L, Alfano G, Li G, Dolcetti L, Evans R, Vicencio JM, Vlckova P, Chen Y, Monypenny J, Gomes CAC, Weitsman G, Ng K, McCarthy C, Yang X, Hu Z, Porter JC, Tape CJ, Yin M, Wei F, Rodriguez-Justo M, Zhang J, Tejpar S, Beatson R, Ng T
EMBO Mol Med 2024 Sep;16(9):2080-2108. Epub 2024 Aug 5 doi: 10.1038/s44321-024-00105-2. PMID: 39103698Free PMC Article
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Cecchini M, Cleary JM, Shyr Y, Chao J, Uboha N, Cho M, Shields A, Pant S, Goff L, Spencer K, Kim E, Stein S, Kortmansky JS, Canosa S, Sklar J, Swisher EM, Radke M, Ivy P, Boerner S, Durecki DE, Hsu CY, LoRusso P, Lacy J
Br J Cancer 2024 Feb;130(3):476-482. Epub 2023 Dec 22 doi: 10.1038/s41416-023-02534-1. PMID: 38135713Free PMC Article
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Ogusu S, Harutani Y, Tozuka T, Saito R, Koyama J, Sakamoto H, Sonoda T, Tsuchiya-Kawano Y, Oba T, Kudo K, Gyotoku H, Nakatomi K, Ariyasu R
Cancer Immunol Immunother 2023 Nov;72(11):3765-3772. Epub 2023 Aug 28 doi: 10.1007/s00262-023-03528-x. PMID: 37638979Free PMC Article
Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M, King G, Spencer K, Borad MJ
Oncologist 2023 Nov 2;28(11):928-943. doi: 10.1093/oncolo/oyad149. PMID: 37390492Free PMC Article
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT
Lancet 2017 Dec 2;390(10111):2461-2471. Epub 2017 Oct 6 doi: 10.1016/S0140-6736(17)31827-5. PMID: 28993052

Recent systematic reviews

The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines.
Dinis-Ribeiro M, Shah S, El-Serag H, Banks M, Uedo N, Tajiri H, Coelho LG, Libanio D, Lahner E, Rollan A, Fang JY, Moreira L, Bornschein J, Malfertheiner P, Kuipers EJ, El-Omar EM
Gut 2024 Sep 9;73(10):1607-1617. doi: 10.1136/gutjnl-2024-333029. PMID: 39122364
Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma.
Catenacci DV, Chao J, Muro K, Al-Batran SE, Klempner SJ, Wainberg ZA, Shah MA, Rha SY, Ohtsu A, Liepa AM, Knoderer H, Chatterjee A, Van Cutsem E
Oncologist 2021 Oct;26(10):e1704-e1729. Epub 2021 Sep 3 doi: 10.1002/onco.13907. PMID: 34288262Free PMC Article
Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y, Moldovan M, Chang Lee R, Hsieh AH, Townsend A, Price T
Cochrane Database Syst Rev 2020 Nov 19;11(11):CD012078. doi: 10.1002/14651858.CD012078.pub2. PMID: 33210731Free PMC Article
Clinicopathological data and treatment modalities for pancreatic vipomas: a systematic review.
Schizas D, Mastoraki A, Bagias G, Patras R, Moris D, Lazaridis II, Arkadopoulos N, Felekouras E
J BUON 2019 Mar-Apr;24(2):415-423. PMID: 31127985

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...